Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (Q37319470)

19 August 2017

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (English)

1 reference

19 August 2017

1 reference

19

Stacey Gabriel

1 reference

19 August 2017

7

Antje Sucker

1 reference

19 August 2017

21

Dirk Schadendorf

1 reference

19 August 2017

22

Levi A Garraway

1 reference

19 August 2017

5

Christian Blank

1 reference

19 August 2017

18

Reinhard Dummer

1 reference

19 August 2017

Eliezer M Van Allen

1

1 reference

19 August 2017

Diana Miao

2

1 reference

19 August 2017

Bastian Schilling

3

1 reference

19 August 2017

Sachet A Shukla

4

1 reference

19 August 2017

Lisa Zimmer

6

1 reference

19 August 2017

Uwe Hillen

8

1 reference

19 August 2017

Marnix H Geukes Foppen

9

1 reference

19 August 2017

Simone M Goldinger

10

1 reference

19 August 2017

Jochen Utikal

11

1 reference

19 August 2017

Jessica C Hassel

12

1 reference

19 August 2017

Benjamin Weide

13

1 reference

19 August 2017

Katharina C Kaehler

14

1 reference

19 August 2017

Carmen Loquai

15

1 reference

19 August 2017

Peter Mohr

16

1 reference

19 August 2017

Ralf Gutzmer

17

1 reference

19 August 2017

Catherine J Wu

20

1 reference

19 August 2017

language of work or name

English

0 references

publication date

10 September 2015

1 reference

19 August 2017

1 reference

19 August 2017

350

1 reference

19 August 2017

207-211

1 reference

19 August 2017

6257

1 reference

Genomic Classification of Cutaneous Melanoma

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Neoantigens in cancer immunotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

The future of immune checkpoint therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Molecular and genetic properties of tumors associated with local immune cytolytic activity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Genetic basis for clinical response to CTLA-4 blockade in melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

A landscape of driver mutations in melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

ContEst: estimating cross-contamination of human samples in next-generation sequencing data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Integrative genomics viewer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054517

Biomarkers in cancer immunotherapy

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26359337

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26359337

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1126/SCIENCE.AAD0095

1 reference

19 August 2017

1 reference

19 August 2017

1 reference